KR20070108158A - 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 - Google Patents
신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 Download PDFInfo
- Publication number
- KR20070108158A KR20070108158A KR1020077016768A KR20077016768A KR20070108158A KR 20070108158 A KR20070108158 A KR 20070108158A KR 1020077016768 A KR1020077016768 A KR 1020077016768A KR 20077016768 A KR20077016768 A KR 20077016768A KR 20070108158 A KR20070108158 A KR 20070108158A
- Authority
- KR
- South Korea
- Prior art keywords
- ngal
- disease
- value
- concentration
- renal
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
환자 번호 | 진단 | u- NGAL 계수 차수 ng /㎖ | s- NGAL 계수 차수 ng /㎖ | p-크레아티닌 계수 차수 μM | 호중구 계수 차수 x 10 9 /㎖ | s- CRP 계수 차수 ㎍/㎖ |
1 | MT, 요량 감소증 | 10 8640 | 10 435 | 10 366 | 11 15.6 | 2 31 |
2 | 대동맥류 파열, 무뇨증, 혈액 투석 | 7 1490 | 9 342 | 11 605 | 7 9.6 | 6 71 |
3 | B-cell ALL, 폐렴 | 9 3800 | 8 330 | 2 63 | 2 2.0 | 10 97 |
4 | 대변 복막염 | 8 2700 | 7 273 | 7 108 | 9 16 | 9 87 |
5 | 구균(S. aureus) 패혈증, ATN | 11 15,700 | 11 922 | 6 103 | 8 13.9 | 8 81 |
6 | AML, 패혈 쇼크 | 6 1030 | 5 146 | 9 164 | 1 <0.1 | 4 56 |
7 | HRS 장구균(E. faecalis) 균혈증 | 3 900 | 3 92 | 3 82 | 5 6.7 | 1 19 |
8 | 혈종, ARDS | 5 1000 | 4 114 | 8 154 | 6 9.5 | 3 37 |
9 | MT | 1 110 | 1 66 | 4 91 | 4 5.7 | 11 103 |
10 | MT | 4 950 | 6 147 | 5 98 | 3 5.0 | 7 81 |
11 | 비장 절제, 구멍 뚫린 횡경막 | 2 130 | 2 79 | 1 30 | 10 19 | 5 62 |
혈장 NGAL | 소변 NGAL | 임상 분류 | ||||
환자 번호 | ng /㎖ | ng /㎖ | 신장 질환 | 패혈증 | 암 | 혈액 투석 |
1 | 92 | 50 | - | - | - | - |
2 | 1005 | 5000 | + | - | - | + |
3 | 151 | 183 | - | + | - | - |
6 | 1320 | 5000 | + | + | - | + |
7 | 777 | 3229 | + | + | + | + |
8 | 712 | 269 | + | + | + | - |
9 | 2941 | 5000 | + | - | - | + |
10 | 3092 | 5000 | + | - | - | + |
11 | 65 | 13 | - | - | - | - |
12 | 2117 | 5000 | + | + | - | + |
15 | 546 | 3128 | + | + | + | - |
17 | 110 | 10 | + | - | - | - |
18 | 135 | 68 | - | - | - | - |
19 | 191 | 2672 | + | + | + | + |
20 | 336 | 304 | - | - | + | - |
21 | 1434 | 5000 | + | + | - | + |
24 | 307 | 1042 | + | - | - | + |
29 | 71 | 50 | - | - | - | - |
30 | 320 | 874 | - | - | - | - |
39 | 1416 | 1073 | + | + | - | - |
41 | 181 | 42 | - | - | - | - |
42 | 115 | 29 | - | - | - | - |
43 | 436 | 176 | + | - | - | - |
44 | 446 | 680 | + | - | - | - |
45 | 270 | 37 | - | - | - | - |
46 | 1962 | 3222 | + | + | + | + |
47 | 222 | 89 | - | + | - | - |
48 | 1040 | 3974 | + | - | - | + |
49 | 228 | 48 | - | - | - | |
51 | 256 | 519 | + | - | + | + |
52 | 294 | 685 | + | + | + | - |
53 | 586 | 1337 | + | + | + | - |
54 | 1376 | 2915 | + | - | + | + |
55 | 1276 | 5000 | + | + | + | + |
57 | 180 | 24 | - | - | - | - |
58 | 716 | 3431 | + | - | - | + |
59 | 108 | 9 | - | + | - | - |
60 | 1219 | 2713 | + | + | + | + |
65 | 460 | 1705 | - | - | + | - |
67 | 1470 | 5000 | + | - | - | + |
69 | 318 | 68 | - | + | - | - |
72 | 175 | 17 | - | - | - | - |
75 | 645 | 3360 | + | - | + | + |
80 | 322 | 328 | - | + | + | - |
82 | 216 | 30 | - | + | - | - |
83 | 259 | 34 | - | + | - | - |
84 | 25 | 20 | - | - | - | - |
85 | 1067 | 370 | + | + | - | + |
86 | 64 | 21 | - | - | - | - |
87 | 276 | 779 | + | - | - | - |
88 | 302 | 1024 | - | + | - | - |
91 | 236 | 17 | - | - | - | - |
93 | 1595 | 5000 | + | + | - | + |
97 | 3491 | 708 | + | + | + | + |
99 | 820 | 401 | + | + | - | + |
100 | 354 | 85 | - | - | + | - |
101 | 1144 | 5000 | + | + | + | + |
104 | 1844 | 2748 | + | + | - | + |
105 | 488 | 4473 | + | - | - | + |
108 | 111 | 46 | - | + | - | - |
Claims (22)
- 인간에 있어 신장 질환의 가능성을 진단, 관찰 또는 측정하는 방법에 있어서, 상기 방법은 신장 질환과 신장에 영향을 미치지 않는 다른 증상 사이의 차이를 구별하는 것으로서, 상기 방법은ⅰ) 인간의 체액 시료 중의 인간 호중구 젤라티나제 결합 리포칼린 (NGAL)의 농도를 측정하는 단계와,ⅱ) 상기 농도를 미리 측정된 절사값과 비교하는 단계를 포함하고, 상기 절사값은 신장에 영향을 미치지 않는 증상과 관련되는 NGAL의 낮은 농도를 배제하도록 선택되고, 절사값 이상의 농도는 신장 질환을 지시하는 것인 인간에 있어 신장 질환의 가능성을 진단, 관찰 또는 측정하는 방법.
- 제1항에 있어서, 상기 시료는 소변 시료이고, 상기 절사값은 250 ng/㎖ 이상, 예컨대 250 ng/㎖ ~ 525 ng/㎖ 범위의 값인 것인 방법.
- 제1항에 있어서, 상기 시료는 혈장 또는 혈청 시료이고, 상기 절사값은 250 ng/㎖ 이상, 예컨대 250 ng/㎖ ~ 525 ng/㎖ 범위의 값인 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 다른 증상은 염증성 질환이고, 상기 절사값은 염증성 질환과 관련된 NGAL의 낮은 농도를 배제하도록 선택되는 것 인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 방법은 신장 질환과 감염성 질환 사이의 차이를 더 구별하고, 상기 절사값은 감염성 질환과 관련된 NGAL의 낮은 농도를 배제하도록 선택되는 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 방법은 신장 질환과 종양성 질환 사이의 차이를 더 구별하고, 상기 절사값은 종양성 질환과 관련된 NGAL의 낮은 농도를 배제하도록 선택되는 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, ⅰ) 및 ⅱ) 단계를 1회 이상 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 24 시간 내에, 예컨대 12 시간 내에, 예를 들어 6 시간 내에, 예컨대 3 시간 내에 ⅰ) 및 ⅱ) 단계를 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 신장 질환의 치료를 시작하거나 끝낸 후에 ⅰ) 및 ⅱ) 단계를 반복하는 단계를 더 포함하는 것인 관찰 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 신장 질환은 허혈 후 신장 손상인 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 신장 질환은 급성 신부전증, 급성 세뇨관 괴사 또는 급성 세뇨관 간질성 신증을 일으킬 수 있는 질환인 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 신장 질환은 신독성제에 의한 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 농도를 제2 절사값과 비교하는 단계를 더 포함하는 것인 방법에 있어서, 상기 제2 절사값은 투석에 의한 환자의 치료를 필요로 할 가능성이 없는 신장 질환 정도와 관련된 NGAL의 낮은 농도를 배제하도록 선택되고, 상기 절사값 이상의 농도는 투석에 의한 치료를 필요로 할 가능성이 높은 심각한 정도의 신장 질환을 지시하는 것인 상기 농도를 제2 절사값과 비교하는 단계를 더 포함하는 것인 방법.
- 제13항에 있어서, 상기 제2 절사값은 1000 ng/㎖ ~ 3000 ng/㎖ 범위로, 예를 들어 1250 ng/㎖, 또는 1500 ng/㎖, 또는 1750 ng/㎖, 또는 2000 ng/㎖, 또는 2250 ng/㎖, 또는 2500 ng/㎖, 또는 2750 ng/㎖인 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, NGAL은 NGAL에 특이적으로 결합하는 분자에 의하여 측정되는 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 체액은 소변인 것인 방법.
- 전술한 항 중 어느 하나의 항에 있어서, 상기 체액은 혈액 또는 혈장 또는 혈청인 것인 방법.
- 인간에 있어 신장 질환의 발병을 관찰하는 방법에 있어서, 상기 방법은ⅰ) 인간의 체액 시료 중 인간 호중구 젤라티나제 결합 리포칼린 (NGAL)의 농도를 측정하는 단계와,ⅱ) 소정의 시간 후에 동일인으로부터 채취한 추가 체액 시료로 단계 ⅰ)을 반복하는 단계와, 및ⅲ) 단계 ⅰ)과 ⅱ)에서 얻은 농도를 비교하여 신장 질환으로 발전하였거나 발전하려 하는지 아닌지를 평가하는 단계를 포함하고, 제2 시료에서 NGAL의 유의적으로 더 높은 농도는 인간이 신장 질환으로 발전하였거나 신장 질환으로 발전하려한다는 것을 지시하는 것인 인간에 있어 신장 질환의 발병을 관찰하는 방법.
- 제18항에 있어서, 상기 유의적으로 더 높은 농도는 NGAL 농도가 50 ng/㎖ 이 상, 예컨대 100 ng/㎖ 이상, 예를 들어 150 ng/㎖ 이상, 예컨대 200 ng/㎖ 이상, 예를 들어 300 ng/㎖ 이상, 예컨대 400 ng/㎖ 이상, 예를 들어 500 ng/㎖ 이상의 상승인 것인 방법.
- 제18항 또는 제19항에 있어서, ⅱ)와 ⅲ) 단계를 1회 이상 반복하는 단계를 더 포함하는 것인 방법.
- 제18항 내지 제20항 중 어느 하나의 항에 있어서, 상기 소정의 시간은 24 시간 이하, 예를 들어 18 시간 이하, 예컨대 12 시간 이하, 예를 들어 6 시간 이하, 예컨대 3 시간 이하인 것인 방법.
- 제18항 내지 제21항에 있어서, 제10항 내지 제17항 중 어느 하나의 항의 특징 중 1개 이상을 더 갖는 것인 방법.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63750304P | 2004-12-20 | 2004-12-20 | |
US60/637,503 | 2004-12-20 | ||
US71930705P | 2005-09-21 | 2005-09-21 | |
US60/719,307 | 2005-09-21 |
Publications (3)
Publication Number | Publication Date |
---|---|
KR20070108158A true KR20070108158A (ko) | 2007-11-08 |
KR100971305B1 KR100971305B1 (ko) | 2010-07-20 |
KR100971305B9 KR100971305B9 (ko) | 2022-07-11 |
Family
ID=36011033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077016768A KR100971305B1 (ko) | 2004-12-20 | 2005-12-20 | 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 |
Country Status (18)
Country | Link |
---|---|
US (3) | US20090170143A1 (ko) |
EP (4) | EP1831699B1 (ko) |
JP (1) | JP4741603B2 (ko) |
KR (1) | KR100971305B1 (ko) |
CN (1) | CN101163971B (ko) |
AT (1) | ATE448484T1 (ko) |
AU (1) | AU2005318689B2 (ko) |
CA (1) | CA2591113C (ko) |
DE (1) | DE602005013288D1 (ko) |
DK (3) | DK2128625T3 (ko) |
ES (4) | ES2703434T3 (ko) |
HK (1) | HK1105454A1 (ko) |
IL (1) | IL183872A (ko) |
NZ (1) | NZ555926A (ko) |
PL (2) | PL3489689T3 (ko) |
SI (1) | SI1831699T1 (ko) |
WO (1) | WO2006066587A1 (ko) |
ZA (1) | ZA200705776B (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150053275A (ko) | 2013-10-24 | 2015-05-18 | (주) 메디컬그룹베스티안 | 화상 중증도 판단 방법 |
KR101657881B1 (ko) * | 2015-03-16 | 2016-09-19 | 대구한의대학교산학협력단 | 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩 |
US9644498B2 (en) | 2013-02-15 | 2017-05-09 | General Electric Company | System and method for reducing back pressure in a gas turbine system |
KR20200017195A (ko) * | 2018-08-08 | 2020-02-18 | 고려대학교 산학협력단 | 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1616184T4 (en) * | 2003-03-27 | 2018-08-13 | Childrens Hospital Med Ct | Method and kit for detecting early onset of renal tubular cell damage |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
EP2035835B1 (en) * | 2006-05-30 | 2011-12-28 | Antibodyshop A/S | Methods for rapid assessment of severity of a trauma |
JP2010500535A (ja) * | 2006-08-07 | 2010-01-07 | アンチボディショップ・アクティーゼルスカブ | 重大な腎損傷を除外するための診断検査 |
EP2500723B1 (en) | 2006-11-14 | 2015-07-08 | Alere San Diego, Inc. | Methods for monitoring and risk prediction in cardiorenal syndrome |
WO2008061149A2 (en) * | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
US8101366B2 (en) * | 2006-12-20 | 2012-01-24 | Antibodyshop A/S | Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an anti-inflammatory and/or anticoagulatory agent |
EP2126562B1 (en) * | 2007-02-23 | 2014-12-31 | Physicians Choice Laboratory Services, LLC | Clinical intervention directed diagnostic methods |
EP2137538B1 (en) | 2007-03-21 | 2014-04-09 | Bioporto Diagnostics A/s | Diagnostic test for renal injury |
US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
WO2009059259A2 (en) * | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
EP2215481B2 (en) * | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
EP2257813A4 (en) * | 2008-03-12 | 2011-11-02 | Univ Columbia | NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE |
US7977110B2 (en) | 2008-06-02 | 2011-07-12 | Children's Hospital Medical Center | Method for distinguishing between kidney dysfunctions |
EP2324355B1 (en) | 2008-08-28 | 2014-01-22 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20100105150A1 (en) * | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
WO2010054025A1 (en) | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use |
AU2009318813B2 (en) * | 2008-11-21 | 2016-11-24 | Future Medical Diagnostics Co., Ltd | Methods, devices and kits for detecting or monitoring acute kidney injury |
US20100233740A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis |
US20100233739A1 (en) * | 2009-02-12 | 2010-09-16 | Jonathan Barasch | Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction |
ES2350078B1 (es) * | 2009-05-19 | 2011-11-15 | Consejo Superior De Investigaciones Científicas (Csic) | Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento |
US20120214177A1 (en) * | 2009-06-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for diagnosis of urosepsis and urinary tract infection |
EP2462443A4 (en) * | 2009-08-07 | 2013-01-30 | Rules Based Medicine Inc | METHODS AND DEVICES FOR DETECTING GLOMERULONEPHRITH AND ASSOCIATED DISORDERS |
CA2772336A1 (en) * | 2009-08-28 | 2011-03-03 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2011053832A1 (en) * | 2009-10-29 | 2011-05-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose sepsis in very low birth weight infants |
US20110195903A1 (en) * | 2009-12-15 | 2011-08-11 | Adra Chaker N | Methods and compositions for detecting recessive familial fsgs and uses thereof |
CN102072960A (zh) * | 2010-03-29 | 2011-05-25 | 武汉生之源生物科技有限公司 | 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法 |
WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
US20130316370A1 (en) * | 2010-10-07 | 2013-11-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN102253217B (zh) * | 2011-04-07 | 2013-08-07 | 武汉生之源生物科技有限公司 | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
TW201250248A (en) * | 2011-04-25 | 2012-12-16 | Kyowa Medex Co Ltd | Prognostication method of renal failure |
NL2007112C2 (en) | 2011-07-14 | 2013-01-15 | Brainlabs B V | Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness. |
US20130062516A1 (en) * | 2011-09-09 | 2013-03-14 | Hsien-Shou Kuo | Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample |
GB2519208A (en) * | 2012-01-11 | 2015-04-15 | Craig Venter Inst J | Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples |
CN102662064A (zh) * | 2012-04-26 | 2012-09-12 | 苏州照康生物技术有限公司 | 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法 |
EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
US9651547B2 (en) | 2013-03-14 | 2017-05-16 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
US9488663B2 (en) | 2013-03-14 | 2016-11-08 | Abbott Point Of Care Inc. | Electrochemical methods and devices for amending urine samples for immunosensor detection |
PL2968443T3 (pl) | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Analogi hepcydyny i ich zastosowania |
KR20230036156A (ko) | 2014-05-16 | 2023-03-14 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | α4β7 인테그린 티오에테르 펩티드 길항제 |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
US11270782B2 (en) | 2014-11-19 | 2022-03-08 | Koninklijke Philips N.V. | Diagnostic method employing HNL |
CN104502596A (zh) * | 2014-12-23 | 2015-04-08 | 温州医科大学 | 一种慢性肾病诊断试剂盒 |
EP3334498B1 (en) | 2015-08-12 | 2023-06-07 | The Trustees of Columbia University in the City of New York | Methods of treating volume depletion and kidney injury |
EP3184116B1 (en) | 2015-12-23 | 2020-09-16 | National Taiwan Normal University | Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease |
TWI581802B (zh) | 2015-12-23 | 2017-05-11 | 國立臺灣師範大學 | 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途 |
CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2018089693A2 (en) * | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
CN109781990A (zh) * | 2018-12-25 | 2019-05-21 | 无锡市人民医院 | 一种β-痕迹蛋白检测试剂盒及制备方法 |
KR102293024B1 (ko) * | 2020-02-07 | 2021-08-24 | 고려대학교 산학협력단 | 혈액 종양 질환 특이적 바이오마커 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635091A (en) * | 1970-08-31 | 1972-01-18 | Frederick D Linzer | Midstream urine specimen and fractional fluid collectors |
IT1074038B (it) * | 1976-08-05 | 1985-04-17 | Simes | Esteri della epinina |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4357343A (en) * | 1981-06-26 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Nutritional composition for management of renal failure |
US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
US4640909A (en) * | 1985-05-07 | 1987-02-03 | J. T. Baker Chemical Company | Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction |
US5939272A (en) * | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5200319A (en) * | 1989-10-27 | 1993-04-06 | The General Hospital Corporation | Diagnosis of glomerulonephritis |
JP2912413B2 (ja) * | 1990-03-28 | 1999-06-28 | 東亜医用電子株式会社 | 粒度分布作成方法 |
US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
SE9401351D0 (sv) | 1994-04-21 | 1994-04-21 | Venge | A method for diagnosis |
US5552313A (en) * | 1994-11-21 | 1996-09-03 | Kansas University | DNA encoding mouse phosphotriesterase-related protein |
US5750345A (en) * | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
US5627034A (en) * | 1995-12-05 | 1997-05-06 | Wisconsin Alumni Research Foundation | Assay for carcinoma proliferative status by measuring NGAL expression level |
PT907735E (pt) * | 1996-05-24 | 2006-06-30 | Biogen Idec Inc | Moduladores da regeneracao de tecidos |
WO1999007740A2 (en) * | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
AUPP784398A0 (en) * | 1998-12-21 | 1999-01-21 | Monash University | Kidney disease detection and treatment |
AU5330200A (en) * | 1999-06-18 | 2001-01-09 | Michigan State University | Method and apparatus for the detection of volatile products in a sample |
US6762032B1 (en) * | 1999-08-23 | 2004-07-13 | Biocrystal, Ltd. | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response |
WO2002029409A2 (en) * | 2000-10-03 | 2002-04-11 | Rowett Research Institute | Method of assaying pyrrole-containing biological compounds |
US6564385B2 (en) * | 2000-10-06 | 2003-05-20 | Mccarthy Daniel J. | Handling device |
AU2002211697B2 (en) * | 2000-10-13 | 2005-12-15 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
FI20010019A (fi) * | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
DE10120614A1 (de) | 2001-04-26 | 2002-10-31 | Sms Demag Ag | Kühlplatte |
EP1666881B1 (en) * | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US20030119209A1 (en) * | 2001-12-21 | 2003-06-26 | Kaylor Rosann Marie | Diagnostic methods and devices |
US6986995B2 (en) * | 2002-02-28 | 2006-01-17 | Prometheus Laboratories, Inc. | Methods of diagnosing liver fibrosis |
US6847451B2 (en) * | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
GB0215509D0 (en) * | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
DK1616184T4 (en) * | 2003-03-27 | 2018-08-13 | Childrens Hospital Med Ct | Method and kit for detecting early onset of renal tubular cell damage |
EP2661963B1 (en) * | 2004-05-06 | 2015-09-16 | The Trustees of Columbia University in the City of New York | Method for diagnosing acute renal failure or chronic renal failure |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
AU2007217861A1 (en) * | 2006-02-17 | 2007-08-30 | Children's Medical Center Corporation | Free NGAL as a biomarker for cancer |
US20080061149A1 (en) * | 2006-09-11 | 2008-03-13 | Colin Tanner | Proximity payment card with security interlock |
US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
US20090123970A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
DE102008025144A1 (de) * | 2008-05-26 | 2009-12-03 | Siemens Aktiengesellschaft | Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln |
-
2005
- 2005-12-20 DK DK09154624.2T patent/DK2128625T3/en active
- 2005-12-20 ES ES17152153T patent/ES2703434T3/es active Active
- 2005-12-20 AU AU2005318689A patent/AU2005318689B2/en not_active Ceased
- 2005-12-20 SI SI200530897T patent/SI1831699T1/sl unknown
- 2005-12-20 ES ES05820913T patent/ES2336345T3/es active Active
- 2005-12-20 NZ NZ555926A patent/NZ555926A/en not_active IP Right Cessation
- 2005-12-20 KR KR1020077016768A patent/KR100971305B1/ko active IP Right Review Request
- 2005-12-20 ES ES09154624.2T patent/ES2622467T3/es active Active
- 2005-12-20 EP EP05820913A patent/EP1831699B1/en not_active Revoked
- 2005-12-20 CA CA2591113A patent/CA2591113C/en active Active
- 2005-12-20 PL PL18195687T patent/PL3489689T3/pl unknown
- 2005-12-20 WO PCT/DK2005/000806 patent/WO2006066587A1/en active Application Filing
- 2005-12-20 CN CN2005800481759A patent/CN101163971B/zh active Active
- 2005-12-20 US US11/722,025 patent/US20090170143A1/en not_active Abandoned
- 2005-12-20 EP EP17152153.7A patent/EP3208616B1/en active Active
- 2005-12-20 EP EP18195687.1A patent/EP3489689B1/en active Active
- 2005-12-20 JP JP2007547181A patent/JP4741603B2/ja active Active
- 2005-12-20 AT AT05820913T patent/ATE448484T1/de active
- 2005-12-20 PL PL05820913T patent/PL1831699T3/pl unknown
- 2005-12-20 ES ES18195687T patent/ES2818028T3/es active Active
- 2005-12-20 DK DK05820913.1T patent/DK1831699T3/da active
- 2005-12-20 DK DK18195687.1T patent/DK3489689T3/da active
- 2005-12-20 EP EP09154624.2A patent/EP2128625B1/en active Active
- 2005-12-20 DE DE602005013288T patent/DE602005013288D1/de active Active
-
2007
- 2007-06-12 IL IL183872A patent/IL183872A/en not_active IP Right Cessation
- 2007-07-13 ZA ZA2007/05776A patent/ZA200705776B/en unknown
- 2007-12-18 HK HK07113788.2A patent/HK1105454A1/xx unknown
-
2015
- 2015-01-08 US US14/592,016 patent/US20150132772A1/en not_active Abandoned
- 2015-09-16 US US14/855,587 patent/US20160003851A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9644498B2 (en) | 2013-02-15 | 2017-05-09 | General Electric Company | System and method for reducing back pressure in a gas turbine system |
KR20150053275A (ko) | 2013-10-24 | 2015-05-18 | (주) 메디컬그룹베스티안 | 화상 중증도 판단 방법 |
KR101657881B1 (ko) * | 2015-03-16 | 2016-09-19 | 대구한의대학교산학협력단 | 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩 |
KR20200017195A (ko) * | 2018-08-08 | 2020-02-18 | 고려대학교 산학협력단 | 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100971305B1 (ko) | 신장 질환용 진단 표지로서의 호중구 젤라티나제 결합리포칼린 (ngal)의 측정 | |
EP2160478B1 (en) | Predictive diagnostics for kidney disease | |
JP5054525B2 (ja) | 腎疾患および腎損傷の早期発見のための方法 | |
US20190170770A1 (en) | Diagnostic Test to Exclude Significant Renal Injury | |
US8313919B2 (en) | Diagnostic test for renal injury | |
Class et al. | Patent application title: DIAGNOSTIC TEST TO EXCLUDE SIGNIFICANT RENAL INJURY Inventors: Lars Otto Uttenthal (Salamanca, ES) Antibodyshop A/s (Gentofte, DE) Kristian Bangert (Holte, DE) Assignees: AntibodyShop A/S |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130709 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140711 Year of fee payment: 5 |
|
J204 | Request for invalidation trial [patent] | ||
FPAY | Annual fee payment |
Payment date: 20160705 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 8 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100000422; TRIAL DECISION FOR INVALIDATION REQUESTED 20160219 Effective date: 20180131 |
|
FPAY | Annual fee payment |
Payment date: 20180705 Year of fee payment: 9 |
|
J202 | Request for trial for correction [limitation] | ||
J202 | Request for trial for correction [limitation] | ||
FPAY | Annual fee payment |
Payment date: 20190703 Year of fee payment: 10 |
|
J121 | Written withdrawal of request for trial | ||
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200003260; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20180406 Effective date: 20190315 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2019300010456; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20190403 Effective date: 20220616 |